title: High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study.
authors.affiliation: Department of Neurodegenerative Disease, Institute of Neurology, and National Hospital for Neurology and Neurosurgery, London, UK.
authors.forename: S J
authors.initials: SJ
authors.lastname: Tabrizi
authors.forename: A M
authors.initials: AM
authors.lastname: Blamire
authors.forename: D N
authors.initials: DN
authors.lastname: Manners
authors.forename: B
authors.initials: B
authors.lastname: Rajagopalan
authors.forename: P
authors.initials: P
authors.lastname: Styles
authors.forename: A H V
authors.initials: AH
authors.lastname: Schapira
authors.forename: T T
authors.initials: TT
authors.lastname: Warner
mesh_terms: D000284:Administration, Oral; D001224:Aspartic Acid / Q000031:analogs & derivatives / Q000097:blood; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D003401:Creatine / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D003404:Creatinine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004734:Energy Metabolism / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006816:Huntington Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D009682:Magnetic Resonance Spectroscopy; D009483:Neuropsychological Tests; D010349:Patient Compliance; D010725:Phosphocreatine / Q000097:blood; D010865:Pilot Projects; D016896:Treatment Outcome; D015854:Up-Regulation / Q000187:drug effects / Q000502:physiology
chemical_list: D010725:Phosphocreatine; D001224:Aspartic Acid; C000179:N-acetylaspartate; D003404:Creatinine; D003401:Creatine